Peripheral Blood Molecular Staging of Breast Cancer: A Prospective Cohort Study Designed to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Peripheral Blood of Stage IV Breast Cancer Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 224
- 试验地点
- 4
- 主要终点
- The prevalence of breast cancer cells in the peripheral blood
研究概览
简要总结
This study is designed to determine whether molecular detection of breast cancer cells in the peripheral blood of Stage IV breast cancer patients is a clinically relevant predictor of progression-free and overall survival. Stage IV breast cancer patients who have measurable breast cancer metastases and are initiating a regimen of systemic therapy are eligible for enrollment. Multi-marker real-time RT-PCR analysis will be performed on peripheral blood specimens from 92 breast cancer patients and 120 healthy volunteers. Peripheral blood specimens from breast cancer patients will be obtained at the time of study entry (prior to initiation of systemic therapy) and at serial time points during follow-up. Subjects will be followed longitudinally until death, although the study has been powered so that the primary objective can be addressed after 12 months of follow-up. Healthy volunteers will be asked to provide a blood sample at time of enrollment but will not be followed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Inclusion Criteria - Stage IV breast cancer patients
- •Patient age must be > 21 years.
- •Patient must have a tissue diagnosis of invasive breast cancer.
- •Patient must have documented evidence of metastatic disease.
- •Patient must have measurable lesions.
- •Patients must be initiating systemic therapy. Patients receiving hormonal therapy, and/or chemotherapy alone or in combination with other therapies are eligible.
- •Patient must have an ECOG performance status of 0, 1, or
- •Patient must be available for follow-up.
- •Patient or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
- •The patient with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patients have been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix).
- •Inclusion Criteria - Healthy volunteers
- •A volunteer will be eligible for inclusion in this study only if ALL of the following criteria apply:
- •Volunteer age must be > 21 years.
- •Volunteer or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
- •Patients with benign breast disease are eligible for enrollment.
- •The volunteer with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided both of the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patient has been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix).
排除标准
- •Exclusion Criteria - Stage IV breast cancer patients
- •A patient will be ineligible for inclusion in this study if ANY of the following criteria apply:
- •No documented metastatic disease.
- •No measurable lesions.
- •Bone only and/or brain metastasis.
- •Patient is not initiating a new regimen of systemic therapy.
研究组 & 干预措施
Stage IV Breast Cancer
Blood draws at baseline before systemic therapy. Blood draw then every 6 weeks for approximately 12 weeks.
干预措施: Blood draw (Other)
Healthy Volunteers
Baseline blood draw.
干预措施: Blood draw (Other)
结局指标
主要结局
The prevalence of breast cancer cells in the peripheral blood
时间窗: 1 year
Specifically, it is predicted that 60% of subjects with Stage IV breast cancer will have evidence of breast cancer cells in the peripheral blood by multi-marker real-time RT-PCR analysis, and that these subjects will experience a significantly decreased progression-free and overall survival.
次要结局
- Compare molecular analyses to the results of the CellSeach assay(Approximately 12 weeks)
- Evaluate the prognostic significance of molecular detection of breast cancer cells in peripheral blood after initiation of systemic therapy.(Until patient death)
- Quantify baseline molecular marker expression levels in the peripheral blood of healthy volunteers(Approximately 12 weeks)